Fate Therapeutics
FATE
44 hedge funds and large institutions have $97.8M invested in Fate Therapeutics in 2015 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 18 increasing their positions, 12 reducing their positions, and 3 closing their positions.
167% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 3
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
50% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 12
13% more funds holding
Funds holding: 39 → 44 (+5)
16% less capital invested
Capital invested by funds: $117M → $97.8M (-$18.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$1.72M |
| 2 |
Allianz Asset Management
Munich,
Germany
|
+$1.32M |
| 3 |
GTC
Ghost Tree Capital
New York
|
+$609K |
| 4 |
TCM
Tufton Capital Management
Hunt Valley,
Maryland
|
+$527K |
| 5 |
RG
Redmile Group
San Francisco,
California
|
+$460K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
-$1.81M |
| 2 |
BC
Broadfin Capital
New York
|
-$1.27M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$254K |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$231K |
| 5 |
EEG
E.E. Geduld
|
-$184K |
FATE Hedge Fund Activity: Q3 2015 in Review
44 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in Fate Therapeutics (FATE) for Q3 2015, worth a combined $97.8M — down 16% from $117M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new FATE positions and 3 closed out — a net gain of 5 holders — while 18 added to existing stakes and 12 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $1.72M. The largest seller was Highland Capital Management (Texas), cutting an estimated $1.81M.
- 44 institutional investors held Fate Therapeutics (FATE) as of Q3 2015, up from 39 in Q2 2015.
- Funds reported $97.8M of Fate Therapeutics stock for Q3 2015, down 16% quarter-over-quarter.
- 8 funds opened new Fate Therapeutics positions in Q3 2015 and 3 closed out, a net change of +5 holders.
- The largest Fate Therapeutics buyer in Q3 2015 was Fidelity Investments, an estimated $1.72M added.
- The largest Fate Therapeutics seller in Q3 2015 was Highland Capital Management (Texas), an estimated $1.81M sold.
Based on aggregated 13F filings for Q3 2015.